Orforglipron Lowered Systolic Blood Pressure 6.1 mmHg vs. 0.8 on Placebo Over 72 Weeks in ATTAIN-1, Post Hoc Analysis Finds
In post hoc analyses of Lilly's Phase 3 ATTAIN-1 (3,127 adults with obesity) and ATTAIN-2 (1,613 adults with obesity and type 2 diabetes) trials, presented at the American Heart Association's Scientific Sessions in Chicago, pooled orforglipron doses lowered office systolic pressure by 6.1 vs. 0.8 mmHg and 4.9 vs. 1.5 mmHg on placebo at 72 weeks. People starting with stage 2 hypertension had the largest drops (15.9 vs. 11.1 and 15.8 vs. 8.2 mmHg), and diastolic pressure fell more than on placebo in ATTAIN-1 but not in ATTAIN-2. Pharmacy Times reported that weight loss explained about 58% and 81% of the systolic change in the two trials.